ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
Industries BiopharmaBiotechnologyMedicalTherapeuticsHeadquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date 2011 Founders Christopher Martin Operating Status Active Last Funding Type Post-IPO Equity Also Known As ADC Legal Name ADC Therapeutics SA
Stock Symbol NYSE:ADCT Company Type For Profit
Contact Email info@adctherapeutics.com Phone Number +1 908-731-5556
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior
therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.